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Introduction: The way to improve the ef-
ficiency of chemotherapy of malignant
gliomas may be combined administra-
tion of alkylating agents and those 
targeted at epithelial growth factor re-
ceptor (EGFR). The patients eligible for
such therapy should show hyperme-
thylation of MGMT (O6-methylguanine-
DNA-methyltransferase) promoter as
well as amplification of EGFR. 
Aim of the study: Preliminary assessment
of frequency of MGMT hypermethylation
and amplification of EGFR co-occurrence
in malignant gliomas in patients diag-
nosed and operated on in the Neuro-
surgery Department, JUMC in Cracow.
Material and methods: 21 consecuti-
ve cases of glioblastoma multiforme
(W 65%, M 35%, age average 51 y). The
methylation status of the MGMT pro-
moter was determined by methylation-
specific PCR (MS-PCR). Before MS-PCR,
genomic DNA was treated with sodium
bisulphite, purified, denatured, precip-
itated and eluted. EGFR amplification was
investigated using the FISH method.
Results: With regards to MGMT methy-
lation status and the occurrence of
EGFR amplification, four groups of tu-
mours (patients) were established: I – hy-
permethylation and amplification (4/21,
19.04%); II – hypermethylation, no am-
plification (6/21, 28.6%); III – no hyper-
methylation with amplification (4/21,
19.04%); IV – no hypermethylation, no
amplification (7/21, 33.3%). 
Conclusions: Theoretically almost one
fifth (19%) of patients with glioblastoma
multiforme, i.e. those featuring MGMT
hypermethylation and EGFR amplifica-
tion, could potentially benefit from bi-
modal chemotherapy with an alkylating
agent and an EGFR blocker. Our results
confirm other reports indicating that
there are no relations between MGMT
methylation and EGFR amplification.
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Introduction
Gliomas are the most common primary brain tumours. According to the most
important features, i.e. vascular proliferation, degree of cellularity/atypia, and
necroses, they are classified into four WHO grades. Glioblastoma multiforme
(GBM) is the grade 4 glioma derived from astrocytes. It constitutes about 55%
of all gliomas, and is more common in male Caucasians. The prognosis in GBM
is extremely poor with median survival rate about 10-15 months and 75% mor-
tality rate in the first 1.5 year from diagnosis. Histopathologically there are two
subgroups of glioblastoma, primary (‘de novo’) and secondary (from the low-
er grade glioma) glioblastoma. Despite years of investigations, the treatment
of glioblastoma is still unsatisfactory [1]. New agents are being investigated.
Significant development of diagnostic methods based on molecular techniques
and neuroimaging has changed the knowledge concerning diagnosis and treat-
ment of central nervous system neoplasms. Glia-derived primary brain tumours
have become a dynamic area of molecular studies. Information from molecular
diagnostics may have crucial importance in the diagnostic and treatment process. 
The way to improve the efficiency of chemotherapy of malignant gliomas
may be the combined administration of alkylating agents and those target-
ed at epithelial growth factor receptor (EGFR). The patients eligible for such
therapy should show hypermethylation of MGMT (O6-methylguanine-DNA-
methyltransferase) promoter as well as amplification of EGFR. 
Material and methods
21 consecutive cases of glioblastoma multiforme were studied: patients 
(W 65%, M 35%, age average 51 y) operated on in the Neurosurgery Depart-
ment of Jagiellonian University Medical College (JUMC) and neuropatholog-
ically diagnosed in the Department of Neuropathology, Chair of Pathomor-
phology, JUMC in Cracow . The methylation status of the MGMT promoter was
determined by methylation-specific PCR (MS-PCR). Before MS-PCR, genom-
ic DNA was treated with sodium bisulphite, purified, denatured, precipitat-
ed and eluted. EGFR amplification was investigated using the FISH method.
O6-methylguanine methyltransferase (MGMT) promoter methy-
lation analysis with methylation-specific PCR (MS PCR)
Tissue samples, not immersed, frozen to the temperature of –80°C directly
after tumour resection were used for analysis. 
DNA isolation sterile removed tissue was fragmented, placed in a 1.5 mL
Eppendorf tube, fast-frozen in liquid nitrogen and kept at a temperature of
–80°C. The genomic DNA isolation from the tumour and from the control tis-
sue was performed using the QIAamp DNA Mini Kit (Qiagen GmbH, Germany)
according to the manufacturer’s protocol.  
DOI: 10.5114/wo.2011.26436  
MGMT promoter methylation detection:
Using the methylation-specific PCR (MSP) method, the lev-
el of methylation in the CpG-rich DNA region of the MGMT
gene promoter was evaluated. The applied method is
based on the chemical modification (deamination) of the DNA
sample with sodium disulphide. In this reaction unmethylated
cytosine is changed to uracil, and in PCR finally to thymine.
PCR involved the use of primers (Polgen, Metabion) specif-
ic for methylated promoter fragment: MET-MGMT-F 
5'-GCACTCTTCCGAAAACGAAAC-3' and MET-MGMT -R 5'-TTTC
GACGTTCGTAGGTTTTC-3', and for detection of umethylat-
ed promoter fragment: UM-MGMT-F 5'-TTTGTGTTTTGAT
GTTTGTAGGTTTTTGT-3' and UM-MGMT -R '-AACTCCACACT
CTTCCAAAAA-3'.
In this way false positive results were eliminated. The PCR
reactions (32 cycles) were performed including an initial de-
naturation of 10 min at 95°C and subsequent denaturation
for 45 s at 95°C, annealing for 45 s at 62°C and extension
for 1.5 min at 72°C. PCR reactions were performed in 30 µl
of 25 mM MgCl2, with 1.2 µl dNTP (Applied Biosystems Inc.),
20 µM of each primer and 0.5 U/µl Gold Taq DNA Polyme-
rase (Applied Biosystems Inc.) Amplification products were
separated on 2% agarose gel (110 V, approx. 25 min) and vi-
sualized by ethidium bromide staining.
Epidermal growth factor receptor (EGFR)
amplification analysis with the FISH method
FISH was done on 4-5-µm-thick formalin-fixed paraffin-
embedded tissue sections (FFPE) using Paraffin Pretreat-
ment Kit (No.32-80120) and LSI/EGFR/CEP 7 FISH Probe kit
(No. 32-191053, Vysis, Inc., Downers Grove, IL, USA). The kit
uses a dual-color probe for determining the number of
copies of EGFR gene (labelled with SpectrumOrange dye)
and the centromeric region of chromosome 7 (7p11.1-q11.1
Alpha Satelite DNA) is labelled with SpectrumGreen dye.
In brief, tissue sections were deparaffinized and dehydra-
ted in 100% ethanol and air dried. Slides were then pre-
treated with 0.2 M hydrochloric acid for 20 minutes (RT),
immersed in Pretreatment Solution at 80°C for 30 minutes
and digested in protease solution for 27 minutes at 37°C.
Then 8 µl of probe was applied on tissue sections and the
slides were denatured (72°C for 5 minutes), hybridized at
37°C overnight in hybridizer MP-16 (Hiperon, Genos). After
hybridization, the slides were washed with Post-Hybridi-
zation Wash Buffer (2xSSC, 0.3% NP-40, pH 7.0-7.5) at 72°C
for 3 minutes. The slides were air-dried and 4’-6’-di -
amidino-2’-phe nylindole (DAPI) counterstain was applied.
Samples were evaluated with the Nikon fluorescence micro-
scope. For the normal numbers of copies of the EGFR gene
and chromosome 7, two orange and two green signals
should be observed, respectively. Three or more orange sig-
nals with two green signals for chromosome 7 indicates
extra copies of the EGFR gene (EGFR amplification). More
than two green signal in the nucleus means polyploidy. 
Results 
The results are summarized in Table 1.
10/21 (47.6%) cases showed MGMT promoter hyperme-
thylation and 8/21 (38.1%) showed amplification of EGFR.
According to the MGMT promoter methylation and EGFR
amplification status the investigated patients form four groups:
• MGMT promoter methylation and EGFR amplification
present: 4/21 (19.04%) (an example illustrated in Fig. 1),
• MGMT promoter methylation present, no EGFR amplifi-
cation: 6/21 (28.6%) (an example illustrated in Fig. 2),
• no MGMT promoter methylation, EGFR amplification pre-
sent: 4/21 (19.04%) (an example illustrated in Fig. 3),
• no MGMT promoter methylation, no EGFR amplification:
7/21 (33.3%) (an example illustrated in Fig. 4).
Discussion
Tumour histopathology and neoplastic cells’ sensitivity to
different strategies of treatment seem to be associated with
specific molecular features. It should be reasonable to adjust
the treatment approach to the particular molecular tumour
phenotype and this is the idea of personalized therapy in on-
cology. At least three molecular markers of clinical significance
in gliomas are already indentified: O6-methylguanine methyl-
transferase (MGMT) promoter methylation, 1p/19q codeletion,
and isocitrate dehydrogenase-1 mutations (IDH1). All of them
are favourable prognostic factors, and some also have predictive
value. Also the classic molecular markers of cancerogenesis,
such as p53 status and epidermal growth factor receptor (EGFR)
amplification, are discussed in gliomas [2]. 
MGMT promoter methylation
O6-methylguanine methyltransferase is a DNA repair pro-
tein. Its function is to remove the alkyl group from the 
O6-guanine position to prevent DNA failure and cell death.
MGMT promoter hypermethylation stops the MGMT tran-
scription. Theoretically, it makes the neoplastic cells’ DNA more
sensitive to damage from alkylating agents. In conclusion,
MGMT promoter methylation has potential predictive val-
ue for this type of chemotherapy (e.g. with temozolomide). 
Clinical trials have already been undertaken to investigate
the correctness of this approach. Thus, in the EORTC trial
22033 – 26033 primary chemotherapy with temozolomide
v. radiotherapy alone in grade II WHO astrocytic brain tumours
has been compared. MGMT status in those patients (strat-
ified for 1p loss already) has been assessed to determine
whether MGMT promoter methylation affects the benefit
from temozolomide therapy. In the CATNON trial (anaplas-
tic gliomas) four patient groups according to 1p/19q loss and
MGMT promoter methylation have been designed and the
efficiency of temozolomide in the concurrent, adjuvant or
both settings with radiotherapy was investigated [3]. The
CODEL project, focused on the newly diagnosed anaplastic
oligodendrogliomas and anaplastic mixed gliomas with
1p/19q codeletion, compared three strategies of treatment:
radiotherapy alone, temozolomide chemotherapy alone, and
radiochemotherapy with temozolomide [4]. 
The most powerful results, according to newly diag-
nosed glioblastoma patients’ management, have been ob-
tained in the EORTC NCIC trial. The EORTC NCIC investigators
reported an increase of the median survival (from 12.1 to 
14.6 months) and of the two-year survival rate (from 10 to 26%)
for patients treated with combined radio- and chemothera-
py with temozolomide. They were able to present a signifi-
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Table 1. Summary of the investigations of MGMT promoter methylation status and amplification of EGFR in glioblastoma
No. MGMT Green Orange EGFR/CEN7 EGFR copies Ploidy;
methylation signalling signalling ratio – 60 cell
status* (CEN7) – 60 cell (EGFR) – no amplification nuclei
nuclei average – 60 cell nuclei – overamplification average
average – ploidy 
1. UNMET 4.2 4.4 1.05 - no amplification 4n
(2-8/nucleus) (2-8/nucleus) - tetraploidy
2. UNMET 3.6 29.9 6.37 - overamplification 4n
(2-4/nucleus) (8-38/nucleus) - tetraploidy 
3. MET 2.8 2.9 1.03 - no amplification 3n
(2-4/nucleus) (2-4/nucleus) - triploidy
4. UNMET 3.1 20.1 6.48 - overamplification 3n
(2-4/nucleus) (15-30/nucleus) - triploidy
5. UNMET 4.9 31.9 6.51 - overamplification 5n
(2-6/nucleus) (16-60/nucleus) - pentaploidy
6. MET 3.2 29.3 9.1 - overamplification 3n
(2-6/nucleus) (16-46/nucleus) - triploidy
7. MET 4.3 4.3 1 - no amplification 4n
(3-8/nucleus) (3-8/nucleus) - tetraploidy
8. MET 3.1 40.2 25.87 - overamplification 3n
(2-4/nucleus) (15-60/nucleus) - triploidy
9. UNMET 3.0 3.1 1.03 - no amplification 3n
(2-5/nucleus) (2-5/nucleus) - triploidy
10. MET 2.1 2.1 1 - no amplification 2n
(1-4/nucleus) (1-4/nucleus)
11. MET 3.3 25.9 7.55 - overamplification 3n
(2-6/nucleus) (22-40/nucleus) - triploidy
12. UNMET 3.8 3.8 1 - no amplification
(2-8/nucleus) (2-8/nucleus) - tetraploidy 4n
13. MET 2.8 2.8 1 - no amplification 3n
(2-3/nucleus) (2-3/nucleus) - triploidy
14. UNMET 2.6 3.3 1.27 - no amplification in 3n
(2-4/nucleus) (2-8/nucleus) most of the nuclei
- triploidy
15. UNMET 3.9 3.9 1 - no amplification 4n
(2-8/nucleus) (2-8/nucleus) - tetraploidy
16. UNMET 2.1 2.1 1 - no amplification 2n
(2-3/nucleus) (2-3/nucleus)
17. UNMET 4.8 5.1 1.1 - no amplification in 5n
(2-6/nucleus) (2-6/nucleus) most of the nuclei
- pentaploidy
18. MET 2 2 1 - no amplification 2n
2/nucleus 2/nucleus
19. MET 2.4 2.4 1 - no amplification 2n
(1-6/nucleus) (1-6/nucleus)
20. UNMET 2.1 24.6 11.74 - overamplification 2n
(1-4/nucleus) (10-40/nucleus)
21. MET 2.7 40 14.8 - overamplification 3n
(2-3/nucleus) (12-60/nucleus) - triploidy
*MET – MGMT promoter methylation present; UNMET – no MGMT promoter methylation 
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cant difference in progression-free survival among the
MGMT promoter methylation group – those treated with ra-
diochemotherapy (temozolomide) have had progression-free
survival of 10.3 months vs. 5.9 months (radiotherapy alone).
It suggests that the MGMT promoter methylation is a posi-
tive predictive factor in temozolomide therapy for glioblas-
toma in newly diagnosed patients. Since then, radiotherapy
alone has no longer been an accepted standard of treatment
in newly diagnosed glioblastoma. MGMT promoter methy-
lation study showed promising results in the CENTRIC trial
also. This project has investigated cilengitide – a first-in-class
integrin targeting polypeptide. It was found that MGMT methy-
lated glioblastoma patients (30 – 35%) responded with a gain
in the progression-free survival from the combined ra-
diochemotherapy (temozolomide plus cilengitide) [5].
The molecular findings are expected to be useful in clin-
ical conditions to facilitate decisions as for the treatment of
choice. MGMT promoter methylation is already an advocated
factor in the treatment decisions in glioblastoma patients.
Based on the MGMT status the homogeneous groups of pa-
tients most likely to benefit from the particular treatment
(alkylating agents) are defined. Unfortunately, available
data do not support any particular treatment in relation to
the molecular features of the tumour. The implementation
of MGMT status evaluation into the glioblastoma treatment
process requires standardization of the MGMT methylation
assessment techniques; for now it is deemed that only methy-
lation-specific PCR can provide repeatable, clinically useful
information, whereas all other methods are of experimen-
tal value. Moreover, even MS-PCR has not met criteria of re-
producibility across the laboratories and the necessity of val-
idation of protocols has been stressed [6]. As a result, MGMT
methylation status evaluated in this way cannot be regarded
as the conditioning factor for temozolomide (the only
proven active agent against glioblastoma) [2].
The current routine histopathological diagnosis of high
grade gliomas does not enable ideal correlation with the
outcome; therefore it is expected that the molecular fea-
tures may help to expand or substantially contribute to
glioma classification. It is well known that the anaplastic
glioma studies need 1p/19q codeletion and MGMT promoter
methylation stratification (CATNON, CODEL) and the new-
ly diagnosed glioblastoma trials need MGMT promoter sta-
tus evaluation (CENTRIC); both molecular markers carry
Fig. 1. MGMT promoter methylation and EGFR amplification pre-
sent (enhanced orange signal due to EGFR gene multiplication) 
Fig. 2. MGMT promoter methylation present, no EGFR amplifica-
tion (characteristic pairs of orange and green signal for both
investigating and control molecular probe of EGFR gene detec-
tion – normal number of EGFR copies)
Fig. 3. No MGMT promoter methylation, EGFR amplification pre-
sent (orange signal for EGFR gene multiplication)
Fig. 4. No MGMT promoter methylation, no EGFR amplification
(as in Fig. 2, orange and green signals form pairs) 
a strong prognostic value, which independently influences
the patients’ outcome [2]. Especially the associations
between different molecular biomarkers require further
investigations (e.g. 1p/19q codeletion and IDH1 mutations
are extremely rare in glioblastomas and might even be con-
sidered as incompatible with the diagnosis of glioblastoma
in the future) [7, 8]. A very basic and still important ques-
tion is the range of MGMT promoter methylation in the
glioblastoma. In our series of unselected and consecutive
cases of GBM, 10/21 (47.6%) showed MGMT promoter
hypermethylation. This result is similar to other reports [9].
EGFR amplification
Epidermal growth factor receptor (EGFR) amplification in
glioblastoma has been widely investigated [10-16]. EGFR
amplification and overexpression is a part of the molecular path-
way leading to secondary glioblastoma development. EGFR
overexpression has been found in 40–50% of glioblastoma cas-
es and is a sign of late tumour progression linked to clinical
malignancy. For this reason, EGFR amplification is considered
an unfavourable prognostic factor in glioblastoma. In about
50% of tumours with EGFR amplification variant III of EGFR
is amplified, which carries worse prognosis in terms of
a poorer survival rate and shorter interval to clinical relapse
[10]. Increased EGFR amplification seems to be related to in-
creased tumour cell proliferation and immortality (resis-
tance to apoptosis), migration, angiogenesis and infiltration.
All of those result from the pathological continuous EGF re-
ceptor activity and consequently activation of the PI3-K/Akt
pathway and MAPK/extracellular signal-regulated kinases 1/2
(ERK1/2) pathway [11]. EGFR signalling inhibition looks promis-
ing as a treatment option in glioblastoma. It is possible in dif-
ferent ways: by monoclonal antibodies blocking the ligand site
in the tumour cell membrane that leads to receptor inter-
nalisation, by ligand-toxin/radioimmuno agents, by intracel-
lular tyrosine kinase inhibitors (EGFR-TKI), or else by decrease
of EGFR expression (antisense oligonucleotides, ribozymes and
small interfering RNA) [10-15]. The clinical trials of EGFR-TKI
erlotinib and gefitinib are ongoing. The first results are con-
troversial [8, 13-16]. While in one study the satisfactory result
of treatment was strongly associated with EGFR overexpres-
sion [11], in another this correlation could not be confirmed
[13]. Recently Peereboom et al. reported negative results of bi-
modal adjuvant treatment of GBM with temozolomide and the
EGFR inhibitor erlotinib [16], though it seems that the ques-
tion has not been definitely solved and the proper selection
of patients for treatment remains a crucial factor.
To sum up, the known glioblastoma molecular status gives
the possibility to define a homogeneous group of patients most
likely to benefit from the particular way of treatment. The in-
vestigation of the co-occurrence of MGMT methylation sta-
tus and amplification of EGFR could result in the recruitment
of patients potentially sensitive to both temozolomide and anti-
EGFR agents and thus in the definition of a more ‘pharma-
cologically homogeneous’ group. Our results suggest that both
MGMT methylation and EGFR amplification segregate inde-
pendently. These results do not differ significantly from
those of Prerana et al., who found EGFR amplification in 30.4%
of GBMs with MGMT hypermethylation (in our material – 40%),
and in 42.1% of cases without MGMT hypermethylation (in our
material – 36.4%) [7]. In our study in about 19% of cases it was
possible to show both molecular biomarkers and therefore sup-
posedly we may estimate that approximately at least 1/5 GBM
patients could benefit from the combined treatment with temo-
zolomide and one of the agents acting via EGFR. 
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